Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

This study looks at how safe and effective a new drug called ONO-4685 is for patients whose T-cell lymphoma has returned or doesn't respond to treatment. Lymphoma is a type of cancer that affects the immune system's cells. Patients must be at least 18 years old and have tried at least two other treatments before joining this study. They also must have certain types of T-cell lymphoma confirmed through tests.

Key Points:

• The study checks the safety of ONO-4685 over 3 months or longer.
• Participants cannot have certain other health conditions, like infections or other cancers.
• Patients cannot have had certain treatments before, like specific antibody therapies.

For participation, patients must have good health in terms of bone marrow, kidney, and liver functions. They should also have a life expectancy of at least three months. However, those with other major health issues or recent infections cannot join. The study aims to see how the drug works and if it helps fight the cancer. Participants must sign a consent form to take part.